Abstract: Maintenance therapy for patients with advanced NSCLC with persistent stable disease(SD) remaining after concurrent chemoradiotherapy or first-line chemotherapy is called consolidation therapy. For patients with unresectable stage ⅢB NSCLC, concurrent chemoradiotherapy is superior to sequential chemoradiotherapy. Following concurrent chemoradiother-apy, Docetaxel administration at 75mg/m² for 2 to 3 cycles is preferable over other treatment plans. The benefit of using Iressa in consolidation therapy remains questionable. For wet stage ⅢB and stage Ⅳ cases, immediate consolidation ther-apy benefits the patients more than treatment given after the disease progresses. Compared with the standard second line therapy, a low dose of Docetaxel at 35mg/m² for 2 to 4 cycles results in the same survival rate, but with less toxicity. Iressa is effective for treating Asian females with adenocarcinoma because their rate of mutation in the gene encoding epidermal growth factor receptor is high. For late stage lung cancer patients, it is essential to make individual treatment plans.